News

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

Christina Prescott, MD, talks about the rate of recurrence of stromal keratitis in the Zoster Eye Disease Study, both in the placebo and in the treatment group.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients.

Perfluorohexyloctane demonstrated rapid symptom relief in patients with dry eye, with effects reported as early as 5 minutes after dosing.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

Nationwide recall of over 70,000 eye care products due to safety risks prompts consumers to return items for full credit.

CCOI transforms ophthalmic innovation by uniting stakeholders, streamlining processes, and prioritizing patient perspectives for faster, impactful solutions.

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.

Carl D. Regillo, MD, shares insights on the VERONA trial of EYP-1901 at the Retina World Congress 2025 meeting held in Fort Lauderdale, Florida.

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential impacts on vision and ocular health.

This large database study explored the link between autoimmune problems and AMD.

In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes.

Perfuse Therapeutics reveals promising results for PER-001, a groundbreaking glaucoma treatment, enhancing vision and ocular health in clinical trials.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.